SCHEMBL6433766

SCHEMBL6433766

CC(C)(C)OC(=O)CN(Cc1cccc(Cl)c1)S(=O)(=O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.51
TAS2R14 Q9NYV8 2/20 0.43
RORC P51449 1/20 0.41
CTSL P07711 1/20 0.41
CTSS P25774 1/20 0.41
DAGLA Q9Y4D2 2/20 0.40
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA4 P22748 3/20 0.39
CA9 Q16790 3/20 0.39
PTGER2 P43116 2/20 0.38
PLG P00747 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
NR1D1 P20393 2/20 0.38
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433131 0.92 PLAU (0.58) PLAUTAS2R14CTSLCTSSDAGLA
SCHEMBL6433815 0.91 PLAU (0.47) PLAUTAS2R14DAGLACA12CA1
SCHEMBL6435665 0.89 PLAU (0.49) PLAUCA12CA1CA2CA4
SCHEMBL6436535 0.88 PLAU (0.49) PLAUPTGER2PLGNR1D1MMP1
SCHEMBL6434142 0.87 PLAU (0.50) PLAUTAS2R14RORCCTSLCTSS
Hydrochloric Acid SCHEMBL6434136 0.86 PLAU (0.49) PLAUTAS2R14RORCCTSLCTSS
SCHEMBL6433730 0.86 PLAU (0.47) PLAUTAS2R14PTGER2
SCHEMBL7409426 0.85 PLAU (0.49) PLAUTAS2R14RORCCTSLCTSS
SCHEMBL6432952 0.84 PLAU (0.47) PLAUPLGNR1D1
SCHEMBL6434727 0.84 PLAU (0.45) PLAUTAS2R14PLGLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TAS2R14 2998/4885RORC 4762/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TAS2R14 2998/4885RORC 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.